20.07.2018 – 10:55
Press release - STADA Launches Anti-Cancer Drug Pemetrexed
STADA Launches Anti-Cancer Drug Pemetrexed
Bad Vilbel, July 20, 2018 - STADAPHARM GmbH, the subsidiary of STADA Arzneimittel AG focused on specialty pharmaceuticals, will from now on distribute cytostatic drug Pemetrexed STADA®.
The drug is used for treating locally advanced, metastasized and non-small cell lung cancer and is a generic of the product Alimta® by Lilly. It generated global sales of around USD 2.06 billion in 2017. In Germany, this product most recently generated sales of around EUR 120 million. In contrast to the original product, Pemetrexed STADA® is supplied not in powder form, but ready-to-use as a concentrate for preparing a solution for infusion.
"With the market launch of Pemetrexed STADA®, we are expanding our portfolio in the field of specialty pharmaceuticals by adding a preparation that has the potential to become one of our five best-selling products in Germany in the medium term," said STADA CEO Claudio Albrecht. "Of course, we are also planning to launch Pemetrexed STADA® internationally as soon as the protection of intellectual property permits."
On July 17, 2018, the German Federal Patent Court had declared the German section of European patent EP 1 313 508 for Alimta®, which would originally have run until 2021, void in the first instance, on the basis of a suit filed by pharmaceutical companies including STADA Arzneimittel AG, paving the way for the market launch by STADA.
About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, non-prescription OTC products and specialty pharmaceuticals, biosimilars in particular. Worldwide, STADA is represented in about 30 countries with roughly 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2017, STADA achieved adjusted Group sales of Euro 2,255.3 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 433.9 million and adjusted net income of Euro 195.6 million. As of December 31, 2017, STADA employed 10,176 people worldwide.
Additional information for journalists: STADA Arzneimittel AG Media Relations Stadastraße 2-18 61118 Bad Vilbel Phone: +49 (0) 6101 603-165 Fax: +49 (0) 6101 603-215 E-Mail: email@example.com Or visit us on the Internet at www.stada.com/press Additional information for capital market participants: STADA Arzneimittel AG Investor & Creditor Relations Stadastraße 2-18 61118 Bad Vilbel / Phone: +49 (0) 6101 603-113 Fax: +49 (0) 6101 603-215 E-Mail: firstname.lastname@example.org Or visit us on the Internet at www.stada.com/investor-relations